<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
<channel>
<title>Daewoong Pharmaceutical Co., Ltd. — News on 6ix</title>
<link>https://6ix.com/company/daewoong-pharma</link>
<description>Latest news and press releases for Daewoong Pharmaceutical Co., Ltd. on 6ix.</description>
<language>en-us</language>
<lastBuildDate>Mon, 04 May 2026 15:00:00 GMT</lastBuildDate>
<generator>6ix RSS</generator>
<atom:link href="https://6ix.com/rss/company/daewoong-pharma" rel="self" type="application/rss+xml" />
<image>
<url>https://6ix-events-pro.s3.amazonaws.com/6ixvideo/logos/org-logo68362b4b78dffbe2df145910.webp</url>
<title>Daewoong Pharmaceutical Co., Ltd.</title>
<link>https://6ix.com/company/daewoong-pharma</link>
</image>
<item>
<title>FreeMind Investments and Daewoong Pharmaceutical Co., Ltd. Invest in General Proximity</title>
<link>https://6ix.com/company/daewoong-pharma/news/freemind-investments-and-daewoong-pharmaceutical-co-ltd-invest-in-general-proximity</link>
<guid isPermaLink="true">https://6ix.com/company/daewoong-pharma/news/freemind-investments-and-daewoong-pharmaceutical-co-ltd-invest-in-general-proximity</guid>
<pubDate>Mon, 04 May 2026 15:00:00 GMT</pubDate>
<description>FreeMind Investments (FMI), a venture capital fund launched in partnership between FreeMind Group and Daewoong Pharmaceutical Co., Ltd., today announced its investment in General Proximity, a San Francisco-based biotechnology company pioneering the next generation of induced proximity medicines.</description>
</item>
<item>
<title>Daewoong Pharmaceutical Hosts 'NABOTA Master Class'… Highlighting Safety Amid Growing Demand for High-Dose, Repetitive Treatments</title>
<link>https://6ix.com/company/daewoong-pharma/news/daewoong-pharmaceutical-hosts-nabota-master-class-highlighting-safety-amid-growing-demand-for-high-dose-repetitive-treatments</link>
<guid isPermaLink="true">https://6ix.com/company/daewoong-pharma/news/daewoong-pharmaceutical-hosts-nabota-master-class-highlighting-safety-amid-growing-demand-for-high-dose-repetitive-treatments</guid>
<pubDate>Fri, 24 Apr 2026 12:00:00 GMT</pubDate>
<description>Daewoong Pharmaceutical (Co-CEOs Seongsoo Park and Changjae Lee) announced that it successfully hosted its global medical education program, the NABOTA Master Class (NMC) Spring in Korea.</description>
</item>
<item>
<title>AEON Biopharma Announces Execution of Exchange Agreement with Daewoong</title>
<link>https://6ix.com/company/daewoong-pharma/news/aeon-biopharma-announces-execution-of-exchange-agreement-with-daewoong-1</link>
<guid isPermaLink="true">https://6ix.com/company/daewoong-pharma/news/aeon-biopharma-announces-execution-of-exchange-agreement-with-daewoong-1</guid>
<pubDate>Mon, 15 Dec 2025 21:05:00 GMT</pubDate>
<description>- AEON and Daewoong Pharmaceutical have executed definitive documentation to exchange $15 million of notes plus accrued interest into new equity, $1.5 million of new notes due 2030, and a cash-exercise warrant for 8 million shares of common stock – - Exchange remains subject to shareholder approval - IRVINE, Calif., Dec. 15, 2025 (GLOBE NEWSWIRE) -- AEON Biopharma, Inc. (“AEON” or the “Company”) (NYSE American: AEON), a biopharmaceutical company seeking accelerated and full-label U.S. market ent</description>
</item>
<item>
<title>Daewoong Pharmaceutical: Third IDMC Reaffirms Safety of Bersiporocin and Recommends Continuation of Global Phase 2 Clinical Trial</title>
<link>https://6ix.com/company/daewoong-pharma/news/daewoong-pharmaceutical-third-idmc-reaffirms-110000975</link>
<guid isPermaLink="true">https://6ix.com/company/daewoong-pharma/news/daewoong-pharmaceutical-third-idmc-reaffirms-110000975</guid>
<pubDate>Mon, 27 Oct 2025 11:00:00 GMT</pubDate>
<description>Daewoong Pharmaceutical (Co-CEOs Seong-Soo Park and Chang-Jae Lee) announced that its first-in-class idiopathic pulmonary fibrosis (IPF) drug candidate Bersiporocin (DWN12088) received a recommendation to continue its global Phase 2 clinical trial following a positive safety review by the third Independent Data Monitoring Committee (IDMC) held on September 23.</description>
</item>
<item>
<title>Daewoong Therapeutics Microneedle Patch Achieves Best-in-Class Bioavailability, Proving the Strength of Its Drug-Delivery Platform</title>
<link>https://6ix.com/company/daewoong-pharma/news/daewoong-therapeutics-microneedle-patch-achieves-best-in-class-bioavailability-proving-the-strength-of-its-drug-delivery-platform</link>
<guid isPermaLink="true">https://6ix.com/company/daewoong-pharma/news/daewoong-therapeutics-microneedle-patch-achieves-best-in-class-bioavailability-proving-the-strength-of-its-drug-delivery-platform</guid>
<pubDate>Wed, 13 Aug 2025 07:36:00 GMT</pubDate>
<description>Daewoong Pharmaceutical (Co-CEOs Seong-Soo Park and Chang-Jae Lee) and Daewoong Therapeutics (CEO Bok-Ki Kang) announced that their proprietary semaglutide microneedle patch achieved more than 80%relative bioavailability compared to the injectable formulation in a pilot human pharmacokinetic study.</description>
</item>
<item>
<title>Salipro Biotech and Daewoong Pharmaceutical Announce Collaboration Agreement to Advance Development of Novel Therapeutics</title>
<link>https://6ix.com/company/daewoong-pharma/news/salipro-biotech-and-daewoong-pharmaceutical-announce-collaboration-agreement-to-advance-development-of-novel-therapeutics</link>
<guid isPermaLink="true">https://6ix.com/company/daewoong-pharma/news/salipro-biotech-and-daewoong-pharmaceutical-announce-collaboration-agreement-to-advance-development-of-novel-therapeutics</guid>
<pubDate>Wed, 11 Jun 2025 04:00:00 GMT</pubDate>
<description>Swedish biotech company Salipro Biotech AB today announced that it has entered into a research collaboration with Daewoong Pharmaceutical Co., Ltd. Daewoong Pharmaceutical gains access to Salipro Biotech's expertise and Salipro® platform for stabilizing challenging membrane proteins (e.g., GPCRs, ion channels, transporters). The collaboration will target a specific membrane protein to aid Daewoong's development of novel small molecule drugs.</description>
</item>
<item>
<title>Daewoong Pharmaceutical Presents Phase 2 Clinical Trial Poster on 'Bersiporocin' at ATS 2025, Highlights Global Patient Demographics</title>
<link>https://6ix.com/company/daewoong-pharma/news/daewoong-pharmaceutical-presents-phase-2-000000262</link>
<guid isPermaLink="true">https://6ix.com/company/daewoong-pharma/news/daewoong-pharmaceutical-presents-phase-2-000000262</guid>
<pubDate>Wed, 04 Jun 2025 00:00:00 GMT</pubDate>
<description>Daewoong Pharmaceutical (Co-CEOs Seongsoo Park and Chang-Jae Lee) announced that it presented interim results from a global Phase 2 clinical trial of its investigational idiopathic pulmonary fibrosis (IPF) treatment candidate Bersiporocin (DWN12088) at the 2025 American Thoracic Society (ATS) International Conference, held from May 16 to 21 in San Francisco.</description>
</item>
</channel>
</rss>